| Name | Title | Contact Details |
|---|
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
far east summit is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AliveDx is a leading diagnostics company that is revolutionizing the field. They provide high quality blood bank reagents called Alba, as well as MosaiQ®, which is the worlds first automated testing platform. Their innovative solutions are designed to...
CLS Health is a multi-specialty medical group with 90+ providers providing comprehensive inpatient & outpatient care in Houston, TX
A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.